|Bid||0.00 x 1400|
|Ask||16.89 x 800|
|Day's Range||12.69 - 13.08|
|52 Week Range||11.83 - 21.41|
|Beta (5Y Monthly)||0.29|
|PE Ratio (TTM)||5.71|
|Earnings Date||Apr 28, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.50|
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The ruling comes a year after the D.C. biotech filed the lawsuit against regulators for imposing a partial clinical hold on a key drug candidate.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) makes the following statement regarding U.S. District Court case 19-cv-30; U.S. Food and Drug Administration (FDA) v. Vanda, in which the U.S. District Court for the District of Columbia ruled in favor of the FDA:
The Supreme Court ruling ensures Vanda’s ability to exclusively market the product until November 2027.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Supreme Court has denied the petition for a writ of certiorari filed by West-Ward Pharmaceuticals (West-Ward), a subsidiary of Hikma Pharmaceuticals, relating to Vanda's U.S. Patent number 8,586,610 (the '610 Patent) for Fanapt®. This order by the U.S. Supreme Court ensures that the '610 patent will remain exclusive at least through November 2, 2027, absent further challenges from other parties.
Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA ...
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that The Physicians Committee for Responsible Medicine, a nonprofit with more than 12,000 doctor members, will present its inaugural Trailblazer Award to Mihael H. Polymeropoulos, MD, Vanda's President and CEO. The honor has been given to acknowledge Dr. Polymeropoulos for his leadership and unwavering commitment to modernize drug testing and improve human safety.
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the third quarter. We get to see hedge funds' thoughts towards the market and […]
WASHINGTON , Nov. 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2019 : The ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
-- Q3 2019 Total net product sales of $59.5 million , a 21% increase year over year -- Vanda reiterates full year 2019 revenue guidance of $215 to $225 million and expects results in the upper half of ...
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]
Conference Call and Webcast to Follow WASHINGTON , Oct. 30, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2019 and ...
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WASHINGTON , Oct. 28, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Anne Sempowski Ward has joined the company's Board of Directors, effective October 28, ...
Questions the routine use of dogs in human drug toxicology studies. WASHINGTON, Oct. 23, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (VNDA) today announced results of a comparative genomics study presented at the 2019 American Society of Human Genetics (ASHG) conference on October 19, 2019, entitled "Using Patterns in Regions of Homozygosity to Evaluate the Use of Dogs as Preclinical Models in Human Drug Development". This means that Beagle dogs are on average 100 times more inbred than humans. In the same study, Vanda researchers examined the degree of inbreeding in the genetic isolate of the Amish in Pennsylvania, which showed that they were approximately 12 times more inbred than the general population. It is well established in the drug efficacy and safety scientific literature that genetic isolates such as Amish populations cannot be generalized for the population at large.
WASHINGTON, Oct. 16, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, urges federal agencies, particularly the U.S. Food and Drug Administration (FDA), to comply with the release of the White House Executive Orders encouraging transparency and accountability when guidance documents are issued without the notice-and-comment rulemaking process required under the Administrative Procedure Act.
HENDERSONVILLE, TN / ACCESSWIRE / October 15, 2019 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 18 years, announces that a purchaser of Vanda ...
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...